|
The American Congress of Obstetricians and Gynecologists (ACOG) reVITALize
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, HRSA
|
NICHD
|
The American College of Obstetricians and Gynecologists and the members of the Women’s Health Registry Alliance lead the reVITALize data definition standardization efforts to harmonize definitions for the data elements used in obstetrics and gynecology. The harmonization of these definitions is critical to assure that data sharing and aggregation can provide the kind of quality information we will need to provide the best care for women and newborns now and in the future.
|
|
The Biomarkers of Nutrition for Development (BOND) program
|
Research Initiative
|
CDC
|
NICHD
|
The Biomarkers of Nutrition for Development (BOND) program is designed to harmonize the process for selection, use, and interpretation of biomarkers to assess exposure, status, and effect of nutrients. BOND has also involved close collaborations with CDC both in terms of the development of the evidence informed reviews and the implementation of the results domestically and internationally. In addition FDA has served as a member of the BOND steering committee and staff have participated in the development of BOND outputs.
|
|
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative
|
Research Initiative
|
FDA
|
NINDS, NCCIH, NIA, NIBIB, NIDA, NIDCD, NIMH
|
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is part of a new Presidential focus aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. Long desired by researchers seeking new ways to treat, cure, and even prevent brain disorders, this picture will fill major gaps in our current knowledge and provide unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought.
|
|
The Critical Path Institute (C-Path) International Neonatal Consortia (INC)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The International Neonatal Consortium (INC). INC is a coalition of industry, academia, patient representatives, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), other governmental agencies, professional organizations, foundations and the Critical Path Institute (C-Path) that will focus on accelerating the development of safe and effective treatments for neonates.
|
|
The Critical Path Institute (C-Path) Global Pediatrics Trials Consortium
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development by facilitating unique partnerships among a wide range of stakeholders, has formed a new consortium, the Global Pediatric Clinical Trials Network Pre-Launch Consortium (“Pre-Launch Consortium”).
According to Dr. Janet Woodcock, Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), “Health care providers must have high-quality, reliable data to inform treatment decisions for their pediatric patients. C-Path has leveraged its expertise and stakeholders to support the development of a first-of-its-kind pediatric clinical trial network. The Pre-Launch Consortium signals an important step toward efficient and sustainable pediatric data collection and development of better treatments for children. I strongly support this effort and look forward to working with this global consortium.”
The mission of the Pre-Launch Consortium will be the formation of an independent non-profit entity that will operate a novel global pediatric clinical trials network (“Network”). The Pre-Launch Consortium will establish the Network, create its organizational and operating framework, and identify its leadership team. This work will involve collaborators from academia, government, scientific, and regulatory agencies, industry, foundations, child health advocacy groups, and other important stakeholders.
|
|
The Effect of Various Drugs on the Retina
|
Other
|
FDA
|
NEI
|
Using powerful in vivo imaging technology, it is possible to view the retina at the cellular level. This collaboration seeks to monitor changes to the retina for drugs that are known to cross the blood/retina barrier to better understand possible toxicity.
|
|
The Environmental Determinants of Diabetes in the Young (TEDDY)
|
Research Initiative
|
CDC
|
NIDDK, NIAID, NICHD, NIEHS
|
This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes.
|
|
The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM)
|
Research Initiative
|
CDC
|
NCI
|
EMBLEM provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: 1. The association of malaria-resistance genes with endemic BL. 2. Host genetic polymorphisms associated with BL using genome-wide association methods. 3. The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. 4. The role of malaria immunology and phenotype of inflammation in BL. 5. The complexity of coinfection with different P. falciparum malaria genotypes in BL. 6. The interaction between helminthic parasites, HIV, malaria, and EBV in BL. 7. The immunohistochemistry and molecular pathology of BL. 8. The impact of malaria, helminthic parasites, and HIV on childhood BL.
|
|
The Federal Tuberculosis Task Force
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA, IHS, OS
|
NIAID, NICHD
|
The Federal Tuberculosis (TB) Task Force is a coalition composed of the Federal agencies and organizations involved in U.S. TB control efforts. Established in 1991, the Task Force facilitates coordination of activities between Federal agencies. It was created by the Director of the Centers for Disease Control and Prevention (CDC) to address the outbreaks of multidrug-resistant (MDR) TB occurring during the 1985-1992 surge in TB cases. The TB Task Force is co-chaired by CDC and NIAID.
|
|
The Healthy Brain Initiative
|
Public Education Campaign
|
ACL, CDC
|
NIA
|
A call to action and a guide to assist in implementing a coordinated approach to moving cognitive health into public health practice.
|